Literature DB >> 11902592

Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article].

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11902592

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

1.  Differential effects of IFN-β on IL-12, IL-23, and IL-10 expression in TLR-stimulated dendritic cells.

Authors:  Jui-Hung Yen; Weimin Kong; Kirsten M Hooper; Frances Emig; Kate M Rahbari; Ping-Chang Kuo; Barbara A Scofield; Doina Ganea
Journal:  J Leukoc Biol       Date:  2015-06-09       Impact factor: 4.962

2.  Screening for balance disorders in mildly affected multiple sclerosis patients.

Authors:  Malou H J Fanchamps; Henrik Gensicke; Jens Kuhle; Ludwig Kappos; John H J Allum; Ozgür Yaldizli
Journal:  J Neurol       Date:  2011-12-21       Impact factor: 4.849

Review 3.  Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis.

Authors:  Michael K Racke; Anne R Gocke; Mark Muir; Asim Diab; Paul D Drew; Amy E Lovett-Racke
Journal:  J Nutr       Date:  2006-03       Impact factor: 4.798

4.  IFNAR signaling directly modulates T lymphocyte activity, resulting in milder experimental autoimmune encephalomyelitis development.

Authors:  Nadia Kavrochorianou; Maria Evangelidou; Melina Markogiannaki; Michael Tovey; George Thyphronitis; Sylva Haralambous
Journal:  J Leukoc Biol       Date:  2015-07-31       Impact factor: 4.962

5.  Resiquimod-Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple Sclerosis.

Authors:  Marta Corsetti; Gabriella Ruocco; Serena Ruggieri; Claudio Gasperini; Luca Battistini; Elisabetta Volpe
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

6.  Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.

Authors:  Frederik Barkhof; Ludwig Kappos; Jerry S Wolinsky; David K B Li; Amit Bar-Or; Hans-Peter Hartung; Shibeshih Belachew; Jian Han; Laura Julian; Annette Sauter; Julie Napieralski; Harold Koendgen; Stephen L Hauser
Journal:  Neurology       Date:  2019-09-04       Impact factor: 9.910

Review 7.  A Quantitative Synthesis of Eight Decades of Global Multiple Sclerosis Research Using Bibliometrics.

Authors:  Ismail Ibrahim Ismail; Mohammed Saqr
Journal:  Front Neurol       Date:  2022-02-24       Impact factor: 4.003

8.  Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity.

Authors:  Dimitris K Karathanasis; Anna Rapti; Adrianos Nezos; Charalampos Skarlis; Constantinos Kilidireas; Clio P Mavragani; Maria Eleftheria Evangelopoulos
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

9.  Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis.

Authors:  Carlos Navas; Carlos A Torres-Duque; Joe Munoz-Ceron; Carlos Álvarez; Juan R García; Luis Zarco; Lázaro A Vélez; Carlos Awad; Carlos Alberto Castro
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.